Last reviewed · How we verify
XOI
XOI is a guanylate cyclase-C (GC-C) agonist that increases intracellular cGMP in intestinal epithelial cells to promote fluid secretion and bowel motility.
XOI is a guanylate cyclase-C (GC-C) agonist that increases intracellular cGMP in intestinal epithelial cells to promote fluid secretion and bowel motility. Used for Chronic idiopathic constipation, Irritable bowel syndrome with constipation (IBS-C).
At a glance
| Generic name | XOI |
|---|---|
| Also known as | allopurinol, febuxostat |
| Sponsor | Ironwood Pharmaceuticals, Inc. |
| Drug class | Guanylate cyclase-C agonist |
| Target | GC-C (guanylate cyclase-C) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
By activating GC-C receptors on the apical surface of intestinal epithelial cells, XOI increases cyclic guanosine monophosphate (cGMP) levels, which triggers chloride and bicarbonate secretion into the intestinal lumen and enhances intestinal muscle contractions. This mechanism increases stool frequency and alleviates constipation by promoting water retention in the bowel and accelerating transit.
Approved indications
- Chronic idiopathic constipation
- Irritable bowel syndrome with constipation (IBS-C)
Common side effects
- Diarrhea
- Abdominal pain
- Nausea
- Headache
Key clinical trials
- Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients (PHASE2)
- Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients (PHASE2)
- A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment (PHASE4)
- Post-Authorisation Safety Study of Lesinurad
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XOI CI brief — competitive landscape report
- XOI updates RSS · CI watch RSS
- Ironwood Pharmaceuticals, Inc. portfolio CI